55040-43-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-hydroxythieno[3,2-c]pyridine-7-carbonitrile is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure and functional groups can be leveraged to create compounds with specific therapeutic properties, targeting a range of diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-bromo-4-hydroxythieno[3,2-c]pyridine-7-carbonitrile is utilized as a precursor in the production of pesticides. Its chemical properties allow for the creation of compounds that can effectively control pests and protect crops, contributing to increased agricultural productivity and food security.
Used in Research and Development:
2-Bromo-4-hydroxythieno[3,2-c]pyridine-7-carbonitrile serves as a valuable compound in scientific research and development. Its unique structure and functional groups make it an interesting subject for studies aimed at understanding its properties, reactivity, and potential applications in various fields, including material science, chemistry, and biology.
Used in Drug Discovery:
As a building block in drug discovery, 2-bromo-4-hydroxythieno[3,2-c]pyridine-7-carbonitrile is employed for its potential to be modified and combined with other molecules to create new pharmaceutical agents. Its presence in a compound may enhance biological activity, improve pharmacokinetic properties, or provide novel mechanisms of action, leading to the development of innovative treatments for various diseases.

Upstream product

• 55040-34-1 4-oxo-4,5-dihydrothieno[3,2-c]pyridine-7-carbonitrile 
• 912368-69-5 (2Z)-3-cyano-3-(2-thienyl)acryloyl azide 
• 912368-68-4 (2Z)-3-cyano-3-(2-thienyl)acryloyl chloride 
• 912368-67-3 (2Z)-3-cyano-3-(2-thienyl)acrylic acid potassium salt 
• 20893-30-5 2-cyanomethylthiophene 

Downstream Products

• 690636-09-0 7-cyano-2-(4'-t-butylphenyl)-4-oxo-4,5-dihydrothieno[3,2-c]-pyridine 
• 912369-00-7 tert-butyl (3S)-3-[(7-cyano-2-phenylthieno[3,2-c]pyridin-4-yl)oxy]piperidine-1-carboxylate 
• 912369-05-2 methyl N-[(benzyloxy)carbonyl]-3-[(2-bromo-7-cyanothieno[3,2-c]pyridin-4-yl)amino]-L-alaninate 
• 912369-36-9 4-{[(3S)-1-(tert-butoxycarbonyl)piperidin-3-yl]amino}-2-phenylthieno[3,2-c]pyridine-7-carboxylic acid 
• 912369-07-4 benzyl [(1S)-2-[(7-cyano-2-phenylthieno[3,2-c]pyridin-4-yl)amino]-1-(hydroxymethyl)ethyl]carbamate 
• 912369-06-3 methyl N-[(benzyloxy)carbonyl]-3-[(7-cyano-2-phenylthieno[3,2-c]pyridin-4-yl)amino]-L-alaninate 
• 912369-51-8 tert-butyl (3S)-3-{[7-cyano-2-(4-piperazin-1-ylphenyl)thieno[3,2-c]pyridin-4-yl]amino}piperidine-1-carboxylate 
• 912369-52-9 tert-butyl (3S)-3-[(7-cyano-2-{4-[4-(methylsulfonyl)piperazin-1-yl]phenyl}thieno[3,2-c]pyridin-4-yl)amino]piperidine-1-carboxylate 
• 912368-71-9 tert-butyl (3S)-3-{[7-cyano-2-(phenyl)thieno[3,2-c]pyridin-4-yl]amino}piperidine-1-carboxylate 

Relevant academic research and scientific papers

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors

A novel series of CHK1 inhibitors based on thienopyridine template has been designed and synthesized. These inhibitors maintain critical hydrogen bonding with the hinge and conserved water in the ATP binding site. Several compounds show single digit nanomolar CHK1 activities. Compound 70 shows excellent enzymatic activity of 1 nM.

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

THIENOPYRIDINES AS IKK INHIBITORS

The invention is concerned with a compound of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein A, W, X, Y, Z and R1 are as defined in the description and the claims. These compounds inhibit IKK and can be

Antiinflammation agents

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.